ArticleCancers2021
CD8+ T Lymphocytes Immune Depletion and LAG-3 Overexpression in Hodgkin Lymphoma Tumor Microenvironment Exposed to Anti-PD-1 Immunotherapy.
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 13 citations in OpenAlex.
- Identification and validation of STEAP3 as a ferroptosis-related biomarker in heart failure.Frontiers in cardiovascular medicine · 2026Article
- The immune cell dynamics in the peripheral blood of cHL patients receiving anti-PD1 treatment.Frontiers in oncology · 2025Article
- Microenvironmental Traits of Classical Hodgkin's Lymphoma in Adolescents and Their Prognostic Impact.Cancers · 2024Article
- A unique expression pattern of LAG3 distinct from that of other immune checkpoints in diffuse large B-cell lymphoma.Cancer medicine · 2023Article
- Resistance mechanisms of immune checkpoint inhibition in lymphoma: Focusing on the tumor microenvironment.Frontiers in pharmacology · 2023Review
- New molecular targets in Hodgkin and Reed-Sternberg cells.Frontiers in immunology · 2023Review
- Advances in the treatment of Hodgkin lymphoma: Current and future approaches.Frontiers in oncology · 2023Review
- Article
- Promising drugs and treatment options for pediatric and adolescent patients with Hodgkin lymphoma.Frontiers in cell and developmental biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.